UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway

Bioorganic & medicinal chemistry letters, 2012-09, Vol.22 (17), p.5445-5450

2012

Volltextzugriff (PDF)

Potent and Orally Bioavailable Non-Peptide Antagonists at the Human Bradykinin B1 Receptor Based on a 2-Alkylamino-5-sulfamoylbenzamide Core

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4642-4644

2004

Volltextzugriff (PDF)

Bradyzide, a potent non‐peptide B2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia

British journal of pharmacology, 2000-01, Vol.129 (1), p.77-86

2000

Volltextzugriff (PDF)

Nonpeptide Bradykinin B2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally-Active Human Bradykinin B2 Receptor Antagonists

Journal of medicinal chemistry, 2002-05, Vol.45 (11), p.2160-2172

2002

Volltextzugriff (PDF)

Bradyzide, a potent non‐peptide B 2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia

British journal of pharmacology, 2009-01, Vol.129 (1), p.77-86

2009

Volltextzugriff (PDF)

1-(2-Nitrophenyl)thiosemicarbazides: A Novel Class of Potent, Orally Active Non-Peptide Antagonist for the Bradykinin B2 Receptor

Journal of medicinal chemistry, 2000-03, Vol.43 (5), p.769-771

2000

Volltextzugriff (PDF)

Potent and Orally Bioavailable Non-Peptide Antagonists at the Human Bradykinin B 1 Receptor Based on a 2-Alkylamino-5-sulfamoylbenzamide Core

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4642-4644

2004

Volltextzugriff (PDF)

Nonpeptide Bradykinin B 2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally-Active Human Bradykinin B 2 Receptor Antagonists

Journal of medicinal chemistry, 2002-05, Vol.45 (11), p.2160-2172

2002

Volltextzugriff (PDF)

Synthesis of 2,9,10-trioxatricyclo[4.3.1.0]decane analogues of resiniferatoxin

Journal of the Chemical Society, Perkin Transactions 1, 1992 (10), p.1229

1992

Volltextzugriff (PDF)

1-(2-Nitrophenyl)thiosemicarbazides: A Novel Class of Potent, Orally Active Non-Peptide Antagonist for the Bradykinin B 2 Receptor

Journal of medicinal chemistry, 2000-03, Vol.43 (5), p.769-771

2000

Volltextzugriff (PDF)

Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4642-4644

2004

Volltextzugriff (PDF)

The stereoselective synthesis of 2,9,10-trioxatricyclo[4.3.1.03,8]decane analogues of resiniferatoxin

Journal of the Chemical Society. Chemical communications, 1991 (4), p.215-217

1991

Volltextzugriff (PDF)

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

The New England journal of medicine, 2023-08, Vol.389 (8), p.687-699

2023

Volltextzugriff (PDF)

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

The Lancet (British edition), 2016-03, Vol.387 (10024), p.1163-1177

2016

Volltextzugriff (PDF)

Reintegration interventions for CPTSD: a systematic review

European journal of psychotraumatology, 2021-01, Vol.12 (1), p.1934789-1934789

2021

Volltextzugriff (PDF)

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

The Lancet (British edition), 2022-01, Vol.399 (10323), p.447-460

2022

Volltextzugriff (PDF)

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

The New England journal of medicine, 2012-04, Vol.366 (16), p.1477-1488

2012

Volltextzugriff (PDF)

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

The lancet oncology, 2023-05, Vol.24 (5), p.443-456

2023

Volltextzugriff (PDF)

Using imaging to combat a pandemic: rationale for developing the UK National COVID-19 Chest Imaging Database

The European respiratory journal, 2020-08, Vol.56 (2), p.2001809

2020

Volltextzugriff (PDF)

Impact of Prostate Cancer Hypofractionation on Patient Reported Outcomes: Baseline to 5 Years Change in the CHHIP Trial

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.S1-S2

2018

Volltextzugriff (PDF)

8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group

European journal of cancer (1990), 2015-09, Vol.51, p.S712-S712

2015

Volltextzugriff (PDF)

A gender-focused multilevel analysis of how country, regional and individual level factors relate to harm from others' drinking

Drugs : education, prevention & policy, 2022, Vol.29 (1), p.13-20

2022

Volltextzugriff (PDF)

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)

European journal of cancer (1990), 2014-09, Vol.50 (14), p.2375-2389

2014

Volltextzugriff (PDF)

5-year patient-reported outcomes of bowel and urinary bother in the CHHiP trial (CRUK/06/016)

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.23-23

2017

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)
Bücher
(1)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway

Potent and Orally Bioavailable Non-Peptide Antagonists at the Human Bradykinin B1 Receptor Based on a 2-Alkylamino-5-sulfamoylbenzamide Core

Bradyzide, a potent non‐peptide B2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia

Nonpeptide Bradykinin B2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally-Active Human Bradykinin B2 Receptor Antagonists

Bradyzide, a potent non‐peptide B 2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia

1-(2-Nitrophenyl)thiosemicarbazides: A Novel Class of Potent, Orally Active Non-Peptide Antagonist for the Bradykinin B2 Receptor

Potent and Orally Bioavailable Non-Peptide Antagonists at the Human Bradykinin B 1 Receptor Based on a 2-Alkylamino-5-sulfamoylbenzamide Core

Nonpeptide Bradykinin B 2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally-Active Human Bradykinin B 2 Receptor Antagonists

Synthesis of 2,9,10-trioxatricyclo[4.3.1.0]decane analogues of resiniferatoxin

1-(2-Nitrophenyl)thiosemicarbazides: A Novel Class of Potent, Orally Active Non-Peptide Antagonist for the Bradykinin B 2 Receptor

Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core

The stereoselective synthesis of 2,9,10-trioxatricyclo[4.3.1.03,8]decane analogues of resiniferatoxin

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Reintegration interventions for CPTSD: a systematic review

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Using imaging to combat a pandemic: rationale for developing the UK National COVID-19 Chest Imaging Database

Impact of Prostate Cancer Hypofractionation on Patient Reported Outcomes: Baseline to 5 Years Change in the CHHIP Trial

8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

A gender-focused multilevel analysis of how country, regional and individual level factors relate to harm from others' drinking

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)

5-year patient-reported outcomes of bowel and urinary bother in the CHHiP trial (CRUK/06/016)

Suchergebnisse filtern